首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

2075217

造血幹細胞移植（HSCT）市場：依移植類型、適應症、應用、最終使用者和地區分類。

Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, By Indication, By Application, By End User, By Region

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

造血幹細胞移植（HSCT）市場預計到2026年將達到39.7億美元，到2033年將達到84.4億美元。預計從2026年到2033年，其複合年成長率將達到11.4%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	39.7億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	11.40%	2033年市場規模預測：	84.4億美元

造血幹細胞移植（也稱為骨髓移植或幹細胞移植）是一種治療癌症（以及其他多種疾病）的方法。了解骨髓的正常功能有助於理解造血幹細胞移植。造血幹細胞移植是目前最有效的癌症治療方法。其他治療方法，例如化療和放射線治療，會對骨髓造成毒性。通常情況下，劑量越高，對骨髓的毒性作用就越大。

造血幹細胞移植主要分為兩種：自體移植和異體移植。自體移植是指採集患者自身的造血幹細胞並冷凍保存，以便在接受高劑量化療或放療前使用。化療或放療結束後，將採集的細胞解凍並輸注給患者。異體移植是指從捐贈者取得造血幹細胞。理想情況下，最好選擇基因組成相似的兄弟姐妹作為捐贈者。

市場動態

預計在預測期內，包括主要市場參與者推出新產品以拓展產品系列的內部成長策略的加強將推動市場成長。例如，2020年1月，基因治療產品供應商Bluebird Bio公司宣佈在德國推出ZYNTEGLO（自體CD34+細胞，編碼BA-T87Q-珠蛋白基因），這是一種用於12歲及以上輸血依賴型地中海貧血B型（TDT）患者的單劑量造血幹細胞（HSC）移植基因療法。 ZYNTEGLO的正式名稱為「富集的基因修飾自體CD34+細胞群，包括經慢病毒載體轉導的、編碼BA-T87Q-珠蛋白基因的造血幹細胞」。

本研究的主要特點：

本報告對全球造血幹細胞移植（HSCT）市場進行了詳細分析，預測了2026年至2033年（以2025年為基準年）的市場規模和複合年成長率（CAGR）。報告也指出了各個細分市場的潛在商機，並說明了該市場極具吸引力的投資提案。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本報告根據以下參數介紹了全球造血幹細胞移植 (HSCT) 市場主要參與者的概況：公司概況、產品系列、主要亮點、財務績效和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球造血幹細胞移植（HSCT）市場報告的目標受群眾外包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師等產業相關人員。
相關人員可以透過利用全球造血幹細胞移植（HSCT）市場分析中使用的各種策略矩陣來簡化其決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第9章競爭情勢

公司簡介
- Pluristem Therapeutics Inc.
- CellGenix GmbH
- Regen Biopharma Inc.
- Lonza Group
- Kiadis Pharma
- Taiga Biotechnologies, Inc.
- Takeda Pharmaceutical Company Limited
- Escape Therapeutics, Inc.
- Bluebird Bio, Inc.
- Talaris Therapeutics, Inc.,
- Marker Therapeutics Inc.
- Stempeutics Research Pvt Ltd.
- CBR Systems Inc.
- Priothera Ltd.
- Eurobio Scientific Group
- Otsuka America Pharmaceutical, Inc.
- Pfizer Inc.
- Sanofi
- FUJIFILM Holdings Corporation

第10章

參考
調查方法

簡介目錄

Product Code: CMI1250

Hematopoietic stem cell transplantation (HSCT) market is estimated to be valued at USD 3.97 Bn in 2026 and is expected to reach USD 8.44 Bn by 2033, growing at a compound annual growth rate (CAGR) of 11.4% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 3.97 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	11.40%	2033 Value Projection:	USD 8.44 Bn

Hematopoietic cell transplantation (also called bone marrow transplantation or stem cell transplantation) is a type of treatment for cancer (and a few other conditions as well). A review of the normal function of the bone marrow will help in the understanding of stem cell transplantation. Hematopoietic cell transplantation is the most effective treatment for cancer. Other treatments, such as chemotherapy and radiation, are toxic to the bone marrow. In general, the higher the dose, the more toxic the effects on the bone marrow.

There are two main types of hematopoietic cell transplantation: autologous and allogeneic. In autologous transplantation, the patient's own hematopoietic stem cells are removed before high-dose chemotherapy or radiation is given, and they are then frozen for storage and later use. After chemotherapy or radiation is complete, the harvested cells are thawed and returned to the patient. In allogeneic transplantation, the hematopoietic stem cells come from a donor, ideally a brother or sister with a similar genetic makeup.

Market Dynamics

The increasing organic growth strategies, such as product launches by key market players to expand their product portfolio are expected to drive market growth over the forecast period. For instance, in January 2020, Bluebird Bio, Inc., a company providing gene therapy products, announced the launch of ZYNTEGLO (autologous CD34+ cells encoding BA-T87Q-globin gene), a one-time gene therapy for patients 12 years of age and older with transfusion-dependent B-thalassemia (TDT) for hematopoietic stem cell (HSC) transplantation in Germany. The full common name for ZYNTEGLO is a genetically modified autologous CD34+ cell-enriched population that contains hematopoietic stem cells transduced with a lentiviral vector encoding the BA-T87Q-globin gene.

Key features of the study:

This report provides an in-depth analysis of the global hematopoietic stem cell transplantation (HSCT) market and provides market size (US$ Billion) and compound annual growth rate (CAGR) for the forecast period 2026-2033, considering 2025 as the base year It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global hematopoietic stem cell transplantation (HSCT) market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study include Pluristem Therapeutics Inc., CellGenix GmbH, Regen Biopharma Inc., Lonza Group, Kiadis Pharma, Taiga Biotechnologies, Inc., Takeda Pharmaceutical Company Limited, Escape Therapeutics, Inc., Bluebird Bio, Inc., Talaris Therapeutics, Inc., Marker Therapeutics Inc., Stempeutics Research Pvt Ltd., CBR Systems Inc., Priothera Ltd., Eurobio Scientific Group, Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi, FUJIFILM Holdings Corporation
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global hematopoietic stem cell transplantation (HSCT) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hematopoietic stem cell transplantation (HSCT) market

Detailed Segmentation:

Global Hematopoietic Stem Cell Transplantation (HSCT) Market , By Transplant Type (Revenue, USD Bn, 2021 - 2033)
Allogeneic
Autologous
Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication (Revenue, USD Bn, 2021 - 2033)
Acute Myeloid Leukemia (AML)
Acute Lymphoblastic Leukemia (ALL)
Hodgkin lymphoma (HL)
Non-Hodgkin Lymphoma (NHL)
Multiple Myeloma (MM)
Others
Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application (Revenue, USD Bn, 2021 - 2033)
Bone Marrow Transplant (BMT)
Peripheral Blood Stem Cells Transplant (PBSCT)
Cord Blood Transplant (CBT)
Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User (Revenue, USD Bn, 2021 - 2033)
Hospitals
Specialty Clinics
Others
Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Company Profiles
Pluristem Therapeutics Inc.
CellGenix GmbH
Regen Biopharma Inc.
Lonza Group
Kiadis Pharma
Taiga Biotechnologies, Inc.
Takeda Pharmaceutical Company Limited
Escape Therapeutics, Inc.
Bluebird Bio, Inc.
Talaris Therapeutics, Inc.
Marker Therapeutics Inc.
Stempeutics Research Pvt Ltd.
CBR Systems Inc.
Priothera Ltd.
Eurobio Scientific Group
Otsuka America Pharmaceutical, Inc.
Pfizer Inc.
Sanofi
FUJIFILM Holdings Corporation

1. Research Objective and Assumption

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Transplant Type
- Market Snippet, By Indication
- Market Snippet, By Application
- Market Snippet, By End User
- Market Snippet, By Region
- Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Test Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Allogeneic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Autologous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

5. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Acute Myeloid Leukemia (AML)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Acute Lymphoblastic Leukemia (ALL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Hodgkin lymphoma (HL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Non-Hodgkin Lymphoma (NHL)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Multiple Myeloma (MM)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

6. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Bone Marrow Transplant (BMT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Peripheral Blood Stem Cells Transplant (PBSCT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Cord Blood Transplant (CBT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

7. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

8. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2021-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2021-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2021-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2021-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2021-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2021 -2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Transplant Type, 2021 -2033, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2021 -2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Application, 2021-2033, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By End User, 2021-2033, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/Region, 2021 -2033, (US$ Bn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Company Profiles
- Pluristem Therapeutics Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- CellGenix GmbH
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Regen Biopharma Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Lonza Group
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Kiadis Pharma
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Taiga Biotechnologies, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Takeda Pharmaceutical Company Limited
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Escape Therapeutics, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Bluebird Bio,Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Talaris Therapeutics, Inc.,
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Marker Therapeutics Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Stempeutics Research Pvt Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- CBR Systems Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Priothera Ltd.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eurobio Scientific Group
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Otsuka America Pharmaceutical, Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Pfizer Inc.
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Sanofi
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- FUJIFILM Holdings Corporation
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies

10. Section

References
Research Methodology
About us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

造血幹細胞移植市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、適應症、應用、最終用戶、地區和競爭格局分類），2021-2031年

FAQ

造血幹細胞移植（HSCT）市場：依移植類型、適應症、應用、最終使用者和地區分類。

Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, By Indication, By Application, By End User, By Region

市場動態

本研究的主要特點：

目錄

第1章：研究目標與前提條件

第2章市場展望

第3章：市場動態、監管與趨勢分析

第4章全球造血幹細胞移植（HSCT）市場：依移植類型分類，2021-2033年

第5章全球造血幹細胞移植（HSCT）市場：依適應症分類，2021-2033年

第6章全球造血幹細胞移植（HSCT）市場：依應用領域分類，2021-2033年

第7章全球造血幹細胞移植（HSCT）市場：依最終用戶分類，2021-2033年

第8章全球造血幹細胞移植（HSCT）市場：依地區分類，2021-2033年

第9章競爭情勢

第10章

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, 2021 - 2033, (US$ Bn)

5. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication, 2021 - 2033, (US$ Bn)

6. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application, 2021 - 2033, (US$ Bn)

7. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User, 2021 - 2033, (US$ Bn)

8. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region, 2021 - 2033, (US$ Bn)

9. Competitive Landscape

10. Section

造血幹細胞移植（HSCT）市場：依移植類型、適應症、應用、最終使用者和地區分類。

Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, By Indication, By Application, By End User, By Region

市場動態

本研究的主要特點：

目錄

第1章：研究目標與前提條件

第2章 市場展望

第3章：市場動態、監管與趨勢分析

第4章 全球造血幹細胞移植（HSCT）市場：依移植類型分類，2021-2033年

第5章 全球造血幹細胞移植（HSCT）市場：依適應症分類，2021-2033年

第6章 全球造血幹細胞移植（HSCT）市場：依應用領域分類，2021-2033年

第7章 全球造血幹細胞移植（HSCT）市場：依最終用戶分類，2021-2033年

第8章 全球造血幹細胞移植（HSCT）市場：依地區分類，2021-2033年

第9章 競爭情勢

第10章

Market Dynamics

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objective and Assumption

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Transplant Type, 2021 - 2033, (US$ Bn)

5. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Indication, 2021 - 2033, (US$ Bn)

6. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Application, 2021 - 2033, (US$ Bn)

7. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By End User, 2021 - 2033, (US$ Bn)

8. Global Hematopoietic Stem Cell Transplantation (HSCT) Market, By Region, 2021 - 2033, (US$ Bn)

9. Competitive Landscape

10. Section

第2章市場展望

第4章全球造血幹細胞移植（HSCT）市場：依移植類型分類，2021-2033年

第5章全球造血幹細胞移植（HSCT）市場：依適應症分類，2021-2033年

第6章全球造血幹細胞移植（HSCT）市場：依應用領域分類，2021-2033年

第7章全球造血幹細胞移植（HSCT）市場：依最終用戶分類，2021-2033年

第8章全球造血幹細胞移植（HSCT）市場：依地區分類，2021-2033年

第9章競爭情勢